News & Updates

Wrist-worn sensor predicts elevated hs-cTnI in ACS patients

A novel transdermal infrared spectrophotometric sensor (transdermal-ISS) worn on the wrist may be used for quick and noninvasive prediction of elevated high-sensitivity cardiac Troponin-I (hs-cTnI) in real world settings, according to a study presented at ACC 2023.

EMPULSE trial confirms the efficacy and safety profile of empagliflozin in patients stabilized in hospital following acute heart failure

Empagliflozin is the first SGLT-2i to significantly improve outcomes for patients with HF in any setting (in-hospital/outpatient), across the full spectrum of HF. Results from the EMPULSE trial showed that patients hospitalized for acute HF who were treated with empagliflozin following stabilization had 36% clinical benefit on the composite of mortality, HF events, and KCCQ-TSS improvement. The EMPULSE trial also provides a reassuring safety profile for empagliflozin that is consistent with previous trials.

Bempedoic acid cuts CV events in statin-intolerant patients

The use of bempedoic acid significantly reduced the risk of major adverse cardiovascular events (MACE) in patients with high cholesterol who are intolerant to statins in the phase III CLEAR* Outcomes trial presented at ACC.23/WCC.

ICD maintains shock function after MRI

Non-magnetic resonance imaging (MRI)-conditional implantable cardioverter defibrillators (ICDs) are effective at treating detected tachyarrhythmias after MRI, with no serious adverse effects on device function seen, reports a study.

GLP-1 RA Diabetes Mellitus Type 2 Diabetes Management Dulaglutide

Moderate carb restriction beneficial to women with metabolic syndrome

A moderately restricted carbohydrate diet (MRCD) appears to yield favourable effects on several cardiometabolic risk factors, including weight and serum triglyceride, in women with metabolic syndrome (MetS), according to a study.